These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 32256115)

  • 1. Acalabrutinib and Its Therapeutic Potential in the Treatment of Chronic Lymphocytic Leukemia: A Short Review on Emerging Data.
    Isaac K; Mato AR
    Cancer Manag Res; 2020; 12():2079-2085. PubMed ID: 32256115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
    Egyed M; Lueff S; Borbely J; Illes A
    Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of acalabrutinib in adults with chronic lymphocytic leukemia.
    Fakhri B; Andreadis C
    Ther Adv Hematol; 2021; 12():2040620721990553. PubMed ID: 33613932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Wolska-Washer A; Robak T
    Expert Rev Hematol; 2022 Mar; 15(3):183-194. PubMed ID: 35296194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An update on acalabrutinib to treat chronic lymphocytic leukemia.
    Blackmon A; O'Brien S
    Drugs Today (Barc); 2021 Jul; 57(7):417-431. PubMed ID: 34268530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Covalent Bruton's Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia.
    Alsouqi A; Woyach JA
    Clin Lymphoma Myeloma Leuk; 2024 May; ():. PubMed ID: 38897870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia.
    Miao Y; Xu W; Li J
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1023-1030. PubMed ID: 34275396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
    Khan Y; O'Brien S
    Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The evolving role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia.
    Gordon MJ; Danilov AV
    Ther Adv Hematol; 2021; 12():2040620721989588. PubMed ID: 33796237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies.
    Abbas HA; Wierda WG
    Front Oncol; 2021; 11():668162. PubMed ID: 34055635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors.
    Bose P; Gandhi V
    Fac Rev; 2021; 10():22. PubMed ID: 33718939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
    Woyach JA; Blachly JS; Rogers KA; Bhat SA; Jianfar M; Lozanski G; Weiss DM; Andersen BL; Gulrajani M; Frigault MM; Hamdy A; Izumi R; Munugalavadla V; Quah C; Wang MH; Byrd JC
    Cancer Discov; 2020 Mar; 10(3):394-405. PubMed ID: 31915195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
    Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
    Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.
    Ghia P; Dlugosz-Danecka M; Scarfò L; Jurczak W
    Leuk Lymphoma; 2021 May; 62(5):1066-1076. PubMed ID: 33427570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.
    Kriegsmann K; Kriegsmann M; Witzens-Harig M
    Recent Results Cancer Res; 2018; 212():285-294. PubMed ID: 30069636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Three-year cardiovascular and non-cardiovascular adverse events in patients with chronic lymphocytic leukemia or small cell lymphocytic lymphoma treated with Bruton tyrosine kinase inhibitors acalabrutinib or ibrutinib: a real-world analysis.
    Nunes RAB; Avezum Á; de Oliveira Marques M; Baiocchi OCCG; Bachour P
    Ann Hematol; 2024 Nov; 103(11):4613-4620. PubMed ID: 39153144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib.
    Vitale C; Gibbons JL; Ferrajoli A
    Onco Targets Ther; 2021; 14():5507-5519. PubMed ID: 35002256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTK Inhibitors in Chronic Lymphocytic Leukemia.
    Gaballa S; Pinilla-Ibarz J
    Curr Hematol Malig Rep; 2021 Oct; 16(5):422-432. PubMed ID: 34599723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to next treatment in patients with chronic lymphocytic leukemia initiating first-line ibrutinib or acalabrutinib.
    Jacobs R; Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Levy MY
    Future Oncol; 2024 Jan; 20(1):39-53. PubMed ID: 37476983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BTK inhibitors and anti-CD20 monoclonal antibodies for treatment-naïve elderly patients with CLL.
    Rogers A; Woyach JA
    Ther Adv Hematol; 2020; 11():2040620720912990. PubMed ID: 32231778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.